<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We examined the determinants of <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in first-degree relatives of African-American type 2 diabetic patients over 5-8 years (median 6) </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 81 healthy subjects (age 41.5 +/- 4.8 years; BMI 31.3 +/- 3.6 kg/m(2)) participated in the study </plain></SENT>
<SENT sid="2" pm="."><plain>Each subject underwent an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) and a frequently sampled intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test at baseline </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin sensitivity index (S(i)) and <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness index (S(g)) were determined by the minimal model method </plain></SENT>
<SENT sid="4" pm="."><plain>Homeostasis model assessment (HOMA) was used to estimate <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR) and beta-cell function (HOMA-%B) </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 18 subjects progressed to either IGT or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (progressors), whereas 19 subjects maintained <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (nonprogressors) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Comparing the progressors and nonprogressors, mean fasting serum <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (95 +/- 8 vs. 80 +/- 14 mg/dl, P &lt; 0.01) and 2-h serum <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (149 +/- 27 vs. 100 +/- 60 mg/dl, P &lt; 0.01) as well as 2-h serum insulin levels (117 +/- 81 vs. 72 +/- 87 microU/ml, P &lt; 0.01) during OGTT were higher at baseline </plain></SENT>
<SENT sid="7" pm="."><plain>Mean <z:hpo ids='HP_0011009'>acute</z:hpo> first-phase insulin secretion (205 +/- 217 vs. 305 +/- 230 microU/ml), HOMA-%B (148 +/- 60 vs. 346 +/- 372, P &lt; 01), S(i) (1.61 +/- 1.13 vs. 2.48 +/- 1.25 x 10(-4) </plain></SENT>
<SENT sid="8" pm="."><plain>min(-1) [microU/ml](-1)), and S(g) (1.48 +/- 0.61 vs. 2.30 +/- 0.97 x 10(-2) </plain></SENT>
<SENT sid="9" pm="."><plain>min(-1)) were lower in the progressors than in the nonprogressors at baseline </plain></SENT>
<SENT sid="10" pm="."><plain>Mean HOMA-IR (3.31 +/- 1.64 vs. 2.36 +/- 1.64) was significantly greater in the progressors than the nonprogressors </plain></SENT>
<SENT sid="11" pm="."><plain>At the time of diagnosis of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> (IGT + <z:mp ids='MP_0002055'>diabetes</z:mp>), HOMA-%B (101 +/- 48 vs. 148 +/- 60, P &lt; 0.001) and HOMA-IR (5.44 +/- 2.55 vs. 3.31 +/- 1.64, P &lt; 0.003) deteriorated in the progressors versus baseline </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: We conclude that nondiabetic, first-degree relatives of African-American type 2 diabetic patients who progressed to IGT and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> manifest triple defects (<z:mp ids='MP_0003059'>decreased insulin secretion</z:mp>, insulin action, and <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness) that antecede the disease </plain></SENT>
</text></document>